Patents by Inventor Roy M. Pollock

Roy M. Pollock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating leukemia
    Patent number: 11633420
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: April 25, 2023
    Assignee: Epizyme, Inc.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott Richard Daigle
  • METHOD OF TREATING LEUKEMIA
    Publication number: 20210268012
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: January 4, 2021
    Publication date: September 2, 2021
    Inventors: Edward J. OLHAVA, Richard CHESWORTH, Kevin W. KUNTZ, Victoria M. RICHON, Roy M. POLLOCK, Scott Richard DAIGLE
  • SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS
    Publication number: 20210252035
    Abstract: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: June 10, 2020
    Publication date: August 19, 2021
    Inventors: Edward J. OLHAVA, Richard CHESWORTH, Kevin W. KUNTZ, Victoria M. RICHON, Roy M. POLLOCK, Scott R. DAIGLE
  • Method of treating leukemia
    Patent number: 10881680
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: January 5, 2021
    Assignee: Epizyme, Inc.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott Richard Daigle
  • INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF
    Publication number: 20200397812
    Abstract: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 24, 2020
    Inventors: Robert A. COPELAND, Victoria M. RICHON, Margaret D. SCOTT, Christopher J. SNEERINGER, Kevin W. KUNTZ, Sarah K. KNUTSON, Roy M. POLLOCK
  • DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA
    Publication number: 20200113923
    Abstract: The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: September 19, 2019
    Publication date: April 16, 2020
    Inventors: Roy M. Pollock, Scott R. Daigle
  • INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF
    Publication number: 20200016162
    Abstract: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.
    Type: Application
    Filed: June 26, 2019
    Publication date: January 16, 2020
    Inventors: Kevin Wayne KUNTZ, Sarah Kathleen KNUTSON, Timothy James Nelson WIGLE, Robert A. COPELAND, Victoria M. RICHON, Margaret D. SCOTT, Christopher J. SNEERINGER, Roy M. POLLOCK
  • TREATMENT OF LEUKEMIA VIA THE ADMINISTRATION OF DOT1L INHIBITOR PINOMETOSTAT
    Publication number: 20200009176
    Abstract: The present invention relates to DOT1L inhibitors.
    Type: Application
    Filed: May 17, 2019
    Publication date: January 9, 2020
    Inventors: Roy M. POLLOCK, Scott R. DAIGLE, Eric HEDRICK, Nigel WATERS, Blythe THOMSON
  • METHOD OF TREATING LEUKEMIA
    Publication number: 20190216838
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: December 10, 2018
    Publication date: July 18, 2019
    Inventors: Edward J. OLHAVA, Richard CHESWORTH, Kevin W. KUNTZ, Victoria M. RICHON, Roy M. POLLOCK, Scott Richard DAIGLE
  • INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF
    Publication number: 20190100552
    Abstract: The present invention relates to DOT1L inhibitors and methods of identifying, designing, or optimizing them. The present invention also relates to crystals of DOT1L-inhibitor complexes, the crystal structures thereof, and the use of the crystal structures. Also disclosed are pharmaceutical compositions containing these DOT1L inhibitors and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: September 18, 2018
    Publication date: April 4, 2019
    Inventors: Edward J. OLHAVA, Richard CHESWORTH, Roy M. POLLOCK, Lei JIN
  • TREATMENT OF LEUKEMIA VIA THE ADMINISTRATION OF DOT1L INHIBITOR PINOMETOSTAT
    Publication number: 20190076455
    Abstract: The present invention relates to a method for the treatment of leukemia and the induction of leukemic blast cell maturation or differentiation via the administration of the DOT1L inhibitor pinometostat (otherwise known as EPZ-5676; CAS Registry number 1380288-87-8) or its N-oxide or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 4, 2015
    Publication date: March 14, 2019
    Inventors: Roy M. POLLOCK, Scott R. DAIGLE, Eric HEDRICK, Nigel WATERS, Blythe THOMSON
  • Methods for treating cancer
    Patent number: 10143704
    Abstract: The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: December 4, 2018
    Assignee: Epizyme, Inc.
    Inventors: Roy M. Pollock, Scott R. Daigle, Eric Hedrick, Nigel Waters, Blythe Thomson
  • Inhibitors of protein methyltransferase DOT1L and methods of use thereof
    Patent number: 10112968
    Abstract: The present invention relates to DOT1L inhibitors and methods of identifying, designing, or optimizing them. The present invention also relates to crystals of DOT1L-inhibitor complexes, the crystal structures thereof, and the use of the crystal structures. Also disclosed are pharmaceutical compositions containing these DOT1L inhibitors and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: October 30, 2018
    Assignee: Epizyme, Inc.
    Inventors: Edward J. Olhava, Richard Chesworth, Roy M. Pollock, Lei Jin
  • SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS
    Publication number: 20180280422
    Abstract: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: November 3, 2017
    Publication date: October 4, 2018
    Inventors: Edward J. OLHAVA, Richard CHESWORTH, Kevin Wayne KUNTZ, Victoria M. RICHON, Roy M. POLLOCK, Scott R. DAIGLE
  • INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF
    Publication number: 20180271892
    Abstract: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.
    Type: Application
    Filed: March 19, 2018
    Publication date: September 27, 2018
    Inventors: Robert A. COPELAND, Victoria M. RICHON, Margaret D. SCOTT, Christopher J. SNEERINGER, Kevin W. KUNTZ, Sarah K. KNUTSON, Roy M. POLLOCK
  • INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF
    Publication number: 20180243315
    Abstract: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.
    Type: Application
    Filed: November 1, 2017
    Publication date: August 30, 2018
    Inventors: Kevin Wayne KUNTZ, Sarah Kathleen KNUTSON, Timothy James Nelson WIGLE, Robert A. COPELAND, Victoria M. RICHON, Margaret D. SCOTT, Christopher J. SNEERINGER, Roy M. POLLOCK
  • Inhibitors of human EZH2, and methods of use thereof
    Patent number: 9949999
    Abstract: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: April 24, 2018
    Assignee: Epizyme, Inc.
    Inventors: Robert A. Copeland, Victoria M. Richon, Margaret D. Scott, Christopher J. Sneeringer, Kevin W. Kuntz, Sarah K. Knutson, Roy M. Pollock
  • METHOD OF TREATING LEUKEMIA
    Publication number: 20170165288
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 15, 2017
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott Richard Daigle
  • INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF
    Publication number: 20170137455
    Abstract: The present invention relates to DOT1L inhibitors and methods of identifying, designing, or optimizing them. The present invention also relates to crystals of DOT1L-inhibitor complexes, the crystal structures thereof, and the use of the crystal structures. Also disclosed are pharmaceutical compositions containing these DOT1L inhibitors and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: June 7, 2016
    Publication date: May 18, 2017
    Inventors: Edward J. Olhava, Richard Chesworth, Roy M. Pollock, Lei Jin
  • Method of treating leukemia
    Patent number: 9597348
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: March 21, 2017
    Assignee: Epizyme, Inc.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott Richard Daigle